Avicenna Alliance: enhanced knowledge, improved decisions, better outcomes
FULL MENU

Patients

The Avicenna Alliance fully embraces “Nothing about us without us” as a guiding principle to achieve person-centric healthcare. We champion Public and Patient Involvement (PPI) to unlock the full potential of research and innovation activities such to ensure relevance and benefit to patients, carers, and society as a whole. PPI will further enable our systematic stakeholder approach to foster in silico medicine technology adoption, mitigate risks of attrition and associated costs, and most importantly, accelerate the translation of research into positive societal impact through collaborative co-creation in our journey towards better healthcare.

Particularly, the PPI task force (TF) has been established within the Policy Development Working Group to pioneer PPI for in silico medicine. Our integrated approach based on 1. creating PPI awareness, 2. supporting implementation, and 3. enabling the requisite culture change has led to a portfolio of tangible outcomes, including, e.g., a full day dedicated to “Involving and serving the patients” at the Avicenna Days (AAD) 2023.

You can find links to our PPI initiatives below, including position papers, workshops, and conferences, with plenty more to come. If you are a patient or PPI-focused organization, join us in reshaping the future of healthcare – send us a message and we can take it from there. Your voice matters, and together, we can drive meaningful change in Digital Health.

Our PPI Initiatives

NEWS

News Avicenna at FDA / MDIC Event in Washington, April 16 - 17

Avicenna at FDA / MDIC Event in Washington, April 16 - 17

Many representatives of the Avicenna Alliance networked with good friends and in silico thought leaders from around the world at the FDA / MDIC symposium on Computation Modeling & Simulation in Washington.

News The European Parliament voted the reform of General Pharmaceutical Legislation (GPL)

The European Parliament voted the reform of General Pharmaceutical Legislation (GPL)

On April 10, the European Parliament overwhelmingly backed the reform of General Pharmaceutical Legislation (GPL), marking a pivotal moment in healthcare regulation. With a resounding majority, both the Directive and Regulation were embraced, reflecting a collaborative effort within the ENVI committee.

News The Avicenna Alliance warmly welcomes Tox By Design into its esteemed ranks!

The Avicenna Alliance warmly welcomes Tox By Design into its esteemed ranks!

Tox by Design is a prominent European toxicological expertise firm specializing in conducting toxicological Risk Assessments (RAs) for various industries such as biotech, pharmaceuticals, cosmetics, medical devices, and API synthesis.

Sign up for our monthly newsletter!

Sign up for our monthly newsletter!

Fill in the fields you find below

Avicenna Alliance is an initiative of:

Avicenna VPH

© 2018-2024 Avicenna Alliance | powered by We Berry